BidaskClub upgraded shares of Heska (NASDAQ:HSKA) from a strong sell rating to a sell rating in a research report report published on Friday morning.
HSKA has been the subject of several other research reports. B. Riley lowered their price objective on shares of Heska from $93.00 to $77.00 and set a neutral rating for the company in a research report on Thursday, March 1st. Canaccord Genuity reissued a buy rating and set a $95.00 price objective on shares of Heska in a research report on Thursday, March 1st. ValuEngine downgraded shares of Heska from a hold rating to a sell rating in a research report on Friday, February 2nd. Sidoti raised shares of Heska from a neutral rating to a buy rating and set a $94.00 price objective for the company in a research report on Monday, February 5th. Finally, Zacks Investment Research downgraded shares of Heska from a hold rating to a sell rating in a research report on Wednesday, January 3rd. Three analysts have rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the stock. The company currently has a consensus rating of Hold and an average target price of $104.08.
Shares of Heska (NASDAQ HSKA) opened at $76.83 on Friday. Heska has a 12 month low of $56.59 and a 12 month high of $115.00. The company has a market cap of $561.29, a P/E ratio of 36.94, a price-to-earnings-growth ratio of 2.13 and a beta of 0.82.
Hedge funds have recently modified their holdings of the company. Royal Bank of Canada increased its position in shares of Heska by 96.9% during the second quarter. Royal Bank of Canada now owns 1,014 shares of the medical research company’s stock worth $103,000 after acquiring an additional 499 shares in the last quarter. SG Americas Securities LLC acquired a new position in Heska during the third quarter worth $108,000. Municipal Employees Retirement System of Michigan boosted its holdings in Heska by 58.9% during the third quarter. Municipal Employees Retirement System of Michigan now owns 2,400 shares of the medical research company’s stock worth $211,000 after purchasing an additional 890 shares during the last quarter. Envestnet Asset Management Inc. boosted its holdings in Heska by 46.7% during the third quarter. Envestnet Asset Management Inc. now owns 2,438 shares of the medical research company’s stock worth $215,000 after purchasing an additional 776 shares during the last quarter. Finally, Quantitative Systematic Strategies LLC acquired a new position in Heska during the fourth quarter worth $206,000. 85.92% of the stock is owned by institutional investors.
COPYRIGHT VIOLATION NOTICE: “Heska (HSKA) Rating Increased to Sell at BidaskClub” was first reported by Markets Daily and is owned by of Markets Daily. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of US and international trademark and copyright laws. The legal version of this story can be read at https://www.themarketsdaily.com/2018/03/12/heska-hska-rating-increased-to-sell-at-bidaskclub.html.
Heska Company Profile
Heska Corporation sells veterinary diagnostic and specialty products. The Company operates through two segments: Core Companion Animal Health (CCA) and Other Vaccines, Pharmaceuticals and Products (OVP). The CCA segment includes, primarily for canine and feline use, blood testing instruments and supplies, digital imaging products, software and services, local and cloud-based data services, allergy testing and immunotherapy, and single use offerings, such as in-clinic diagnostic tests and heartworm preventive products.
Receive News & Ratings for Heska Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska and related companies with MarketBeat.com's FREE daily email newsletter.